Myocardial perfusion as an indicator of graft patency after coronary artery bypass surgery

Circulation
A J KolibashR P Lewis

Abstract

Stress and resting myocardial perfusion were assessed in 38 patients who received 96 grafts. Stress perfusion was evaluated with thallium-201 and resting myocardial blood flow distribution with radiolabeled particles. When both stress and rest perfusion were normal, graft patency was 82% (51 of 62 grafts). Graft patency was also high (81%, 13 of 16) in areas where stress perfusion abnormalities resolved or become less apparent at rest. However, when stress perfusion defects remained unchanged at rest, the graft was likely to be occluded (73%, 11 of 15). Maintenance of normal rest perfusion or improvement of rest perfusion postoperatively was also associated with a high graft patency rate (80%, 35 of 44), whereas the development of new rest perfusion defects postoperatively implied graft occlusion (86%, six of seven).

References

Aug 1, 1978·The American Journal of Cardiology·B H GreenbergW W Parmley
Nov 1, 1979·British Heart Journal·J A SbarbaroL Resnekov
Mar 1, 1978·Circulation·H D McIntosh, J A Garcia
Jul 3, 1975·The New England Journal of Medicine·E D Mundth, W G Austen

❮ Previous
Next ❯

Citations

May 29, 1999·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·K UeyamaM Ohnaka
Dec 16, 1998·The International Journal of Angiology : Official Publication of the International College of Angiology, Inc·E TamiyaK Asano
Aug 1, 1983·Journal of the American College of Cardiology·C R McKayP A Ebert
Jan 1, 1984·Journal of the American College of Cardiology·R G BrindisK Turley
Jul 1, 1982·The New England Journal of Medicine·M J Sands
Dec 1, 1982·The American Journal of Cardiology·A J BudaH Meindok

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.